DFMO to prevent return of high-risk or relapsed medulloblastoma
Part of Cancer clinical trials.
This Phase 2 study tests DFMO (a maintenance medicine) to help stop medulloblastoma from coming back or worsening after prior treatment. It focuses on children and young people with specific high-risk tumor types or tumors that have returned or not responded well to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with medulloblastoma and the tumor subtype was identified by special lab tests (Nanostring or methylation testing).
- You must be between 0 and 21 years old at diagnosis.
- Before starting DFMO, you need updated disease staging: MRI of the brain and spine (and a spinal fluid test or bone marrow test only if they were previously positive).
- Your current scans must show either no active disease or stable leftover tumor that is small (and not growing on two scans at least 6 weeks apart).
- You usually must start DFMO within 60 days after your last standard chemotherapy dose (with extra timing rules if you had high-dose chemo plus stem cell transplant).
- You must meet safety checks: good performance/energy level (Lansky or Karnofsky score at least 50%), enough blood counts and organ function, and no uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a drug called DFMO for children and young adults with certain rare cancers that have not responded to standard treatments or have come back. DFMO may help stop cancer cells from growing.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This trial compares two standard treatment plans for young children with a specific type of medulloblastoma (a brain tumor). It looks at how each treatment affects thinking and learning over time, to see which one helps children do better in the long run.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.